Look Towards A New Future

May 1, 2012

Therapy Trends: Multiple Sclerosis

An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends.

Driven by in-depth interviews with the world’s leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.

Reasons to Buy

The deliverables

Therapy Trends: Multiple Sclerosis is delivered in two complimentary formats:

Therapy Trends Intelligence Report: a concise, focused, in-depth market intelligence research report that examines the range of current and late-stage pipeline drugs to determine future trends in the treatment and diagnosis of MS, and assess the commercial impact on the MS market landscape.

Therapy Trends Impact Assessments: dynamic analyst briefings evaluating the impact of events in the MS market over the next 12 months, delivered to you within days of a significant event happening

Key Benefits
  • Unmet needs analysis to identify opportunities and address the challenges facing disease management
  • Strategic mapping of future treatment algorithms based on KOL insight
  • Commercial and clinical analysis of pipeline therapies
  • In-depth, dynamic event impact assessments to evaluate current strategies and plans against new conditions
  • Align investment and resource planning to future trends
  • Know the story driving the trends
Multiple Sclerosis Therapy Trends

Published: April 2012
No. of Pages: 160
Price: Single User License: US $ 4995 Corporate User License : US $ 14995


Executive Summary
Current multiple sclerosis marketplace
> Current treatment landscape
> Multiple sclerosis market definition
> Current market overview
> Current therapies
> Cross trial comparisons is not an ideal assessment
> Gilenya (fingolimod; Novartis) trends
> Gilenya has first oral to market advantage
> Gilenya raises bar for pipeline therapies entering the market
> Deaths mar Gilenya's side effect profile and positions drug as a second line
> Vigilance program is cumbersome and likely to restrict access
> Gilenya's high price will restrict use
> Clinical trials in progressive multiple sclerosis ongoing
> Tysabri (natalizumab; Biogen/Elan) trends
> Tysabri is the most effective approved multiple sclerosis therapy
> PML fears positions drug as second or later line
> JCV test will promote use and allay fears
> Progressive multiple sclerosis trials ongoing for Tysabri
> Copaxone (glatiramer acetate; Teva) trends
> Copaxone is the leading selling multiple sclerosis therapy
> Teva fights generic Copaxone applications
> Interferon betas (Avonex, Betaseron, Rebif, Extavia) trends
> Interferons are the mainstay of multiple sclerosis treatment
> Needles have evolved to avoid injection site reactions
> Biosimilar guidelines in place for interferons
> Current treatment algorithm
> Multiple sclerosis unmet needs
> Unmet need 1: Efficacy for progressive subtypes
> Unmet need 2: Therapies offering better clinical profiles
> Unmet need 3: Drugs to halt or repair neuronal damage
> Unmet need 4: Improving multiple sclerosis induced cognition dysfunction
> Unmet need 5: Need for improved adherence

Browse more Pharmaceutical Reports @